Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation
Acerta Pharma BV
Patients will be randomised into one of three treatment Arms. In the first Arm, patients will receive oral Acalabrutinib in combination with Venetoclax. In the second Arm, patients will receive oral Acalabrutinib in combination with Venetoclax with or without the immunotherpy drug, Obinutuzumab. In the final treatment Arm, patients will receive the investigators choice of chemoimmunotherapy, containing Fludarabine, Cyclophosphamide and Rituximab (FCR).